Neurogene INC Form 4 insider transactions

Neurogene Inc. reports insider Christine Cvijic sold shares valued at approximately $36 per share as part of a pre-arranged trading plan.

Neurogene Inc. President and CFO Christine Mikail Cvijic has sold a significant number of company shares through a pre-arranged trading plan.

Director Keith Woods refiles a Form 4 to correct an administrative CIK error regarding a previously reported stock option grant.

Director Keith Woods refiled a Form 4 to correct a CIK number error regarding a previously reported stock option grant.

Director Keith Woods filed an amendment to a Form 4 to correct a CIK number error regarding a previously reported stock option grant.

Neurogene Inc. President and CFO Christine Mikail Cvijic sold 9,600 shares of common stock via a pre-arranged 10b5-1 trading plan.

Neurogene Inc. reports a significant stock option grant to Chief Commercial Officer Christina Shafer, with vesting over several years.

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold 2,558 shares of common stock at a weighted average price of $21.6247 to cover tax withholding obligations from a restricted stock unit vesting.

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, sold a total of 6,797 shares of common stock on March 13, 2026, through a pre-arranged 10b5-1 trading plan.

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold common stock on March 13, 2026, to cover tax withholding responsibilities related to a vested Restricted Stock Unit award.

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold 4,800 shares of common stock for approximately $25.11 per share under a pre-arranged 10b5-1 plan.

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, was granted 16,500 restricted stock units, increasing his total beneficial ownership to 37,294 units.

Neurogene Inc.'s Chief Medical Officer, Julie Jordan, received new equity awards including restricted stock units and stock options.

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, received new grants of restricted stock units and stock options, increasing her beneficial ownership.

Neurogene Inc.'s CEO, Rachel McMinn, reported the acquisition of 25,900 restricted stock units and 155,100 stock options, alongside a correction to previously reported beneficial ownership.

Neurogene Inc. Director Rohan Palekar was granted 12,050 non-qualified stock options with an exercise price of $17.64, vesting monthly over one year.

Neurogene Inc. Director Robert Baffi was granted 12,050 non-qualified stock options with an exercise price of $17.64 per share, vesting monthly over one year.

Neurogene Inc. Director Sarah B. Noonberg was granted non-qualified stock options for 12,050 shares at an exercise price of $17.64.

Neurogene Inc. Director Cory S. Freedland was granted 12,050 non-qualified stock options with an exercise price of $17.64, vesting monthly over one year.

Neurogene Inc. Director Keith Woods was granted 12,050 non-qualified stock options with an exercise price of $17.64, vesting monthly over one year.

Neurogene Inc. director Robert Baffi received a grant of 12,050 non-qualified stock options with a vesting schedule over one year, as detailed in a recent SEC Form 4 filing.

Neurogene Inc. Director Robert Keith Woods was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Neurogene Inc. Director Rohan Palekar was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Neurogene Inc. director and 10% owner Cory S. Freedland was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Neurogene Inc. Director Sarah B. Noonberg was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Stuart Cobb, Chief Scientific Officer of Neurogene Inc., reports the sale of 6,797 shares of common stock at a weighted average price of $15.1542, pursuant to a pre-arranged 10b5-1 trading plan.

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, reports the acquisition of restricted stock units and stock options in a recent SEC filing.

Christine Mikail Cvijic, President and CFO of Neurogene Inc., reports the acquisition of restricted stock units and stock options.

Chief Medical Officer Julie Jordan reports acquiring 8,400 shares of common stock and options to purchase 50,300 shares of Neurogene Inc. stock.

Neurogene Inc. CEO Rachel McMinn reports the acquisition of 23,900 restricted stock units and 143,500 stock options.